#SRDX QTR DATE FULL#

Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.23) to $(1.08).

Surmodics expects fiscal 2022 diluted GAAP EPS, which reflects continued investments to accelerate the Company’s strategy, to a range from a loss per share of $(1.50) to $(1.35), from the previous range of $(1.70) to $(1.35).

#SRDX QTR DATE FULL#

Surmodics expects full year fiscal 2022 revenue to range from $97 million to $99 million, from the previous range of $98 million to $101 million. Surmodics is revising its fiscal year 2022 revenue guidance to reflect expected softness in customer demand and raising its fiscal year 2022 EPS guidance to reflect solid year-to-date results. Surmodics reported $3.5 million of cash used in operating activities and $0.9 million in capital expenditures for the third quarter of fiscal 2022. On a non-GAAP basis, loss per share in the third quarter of fiscal 2022 was $(0.34), compared to $(0.17) in the same prior-year quarter.Īs of June 30, 2022, Surmodics reported cash and investments totaling $22.1 million and $10 million in outstanding borrowings on its $25 million line of credit. In Vitro Diagnostics revenue was $7.3 million for the third quarter of fiscal 2022, compared to $7.1 million in the prior-year quarter, an increase of 3%.ĭiluted GAAP loss per share in the third quarter of fiscal 2022 was $(0.41), compared to $(0.24) in the same prior-year period. (“Abbott”) for the SurVeil TM drug-coated balloon (“DCB”). Medical Device revenue in both the third quarter of fiscal 20 includes $1.0 million from our Development and Distribution Agreement with Abbott Vascular, Inc. Medical Device revenue was $17.5 million for the third quarter of fiscal 2022, compared to $16.8 million in the prior-year period, an increase of 5%. Total revenue for the third quarter of fiscal 2022 was $24.9 million, compared to $23.9 million in the prior-year period. Third Quarter Fiscal 2022 Financial Results “Importantly, we are demonstrating early and promising commercial viability for our Pounce TM and Sublime TM products with our commercial footprint and customer base.” “We delivered solid financial results that were in line with our expectations, while continuing to make meaningful investments in our growth initiatives,” said Gary Maharaj, President and CEO of Surmodics, Inc.

GAAP EPS of $(0.41), non-GAAP EPS of $(0.34)įourth consecutive quarter of double‐digit product sales growth year‐over‐year

Revenue of $24.9 million, an increase of 4% year-over-year Summary of Third Quarter and Recent Highlights (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 third quarter ended Jand updated its financial outlook for its fiscal 2022. EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-Surmodics, Inc.